Endometriosis can affect everyday life through pain and other persistent symptoms. In June 2025, NICE published guidance on linzagolix, adding an oral option for a defined group of patients.
The recommendation
NICE recommends linzagolix with hormonal add-back therapy as an option for adults of reproductive age who have already had medical or surgical treatment for endometriosis. This is more specific than describing the medicine as a treatment available to everyone with the condition.
Why another option matters
Treatment decisions depend on symptoms, previous care and individual circumstances. An additional medicine gives patients and clinicians another possibility to discuss within that assessment. It should not be presented as a cure or a guarantee that surgery or other treatment will be unnecessary.
Finding the full details
The NICE appraisal explains the recommendation and its conditions. Anyone considering treatment needs an individual conversation with their clinical team about suitability, benefits and possible adverse effects. This article describes the guidance rather than providing prescribing instructions.
